Navigation Links
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
Date:3/31/2009

itigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for Valortim(R). At this point there can be no assurance that Valortim(R) will be shown to be safe and effective and approved by regulator
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... ® Complete Knee System. ... th year since Zimmer first introduced the NexGen knee ... date, more than five million implantations of the NexGen knee ... the NexGen knee demonstrates the importance of design innovation and ...
(Date:3/27/2015)... March 27, 2015 Report Details  ... leading ophthalmic drug companies  What does the ... ophthalmic industry ? Visiongain,s brand new report shows you ... prospects there. Our 242-page report provides 185 ... in the industry and the future market prospects. Our ...
(Date:3/27/2015)... The International Myeloma Foundation (IMF) – improving ... toward prevention and a cure – today commended Representative ... resolution (H. Res. 174) that supports the designation of ... Awareness Month." Currently there are more than ... 110,000 new cases are diagnosed yearly, according to the ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... Calif., Dec. 9, 2010 Ambry Genetics, a global ... sciences industries, announced today that it has officially launched ... Genetics has been an early adapter of Illumina sequencing ... Certified Service Provider. (Logo:   http://photos.prnewswire.com/prnh/20090428/LA06744LOGO ...
... 9, 2010 A new study shows that ... hormonal therapy tamoxifen in patients with hormone-receptor positive/human ... cancer who have been previously treated with an ... tamoxifen alone. These results were presented today at ...
Cached Medicine Technology:Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 3Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 4Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 5Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 6Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 7Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 8Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 9Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 10Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 11
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with ... provider for the 2015 and 2016 season. As the Storm’s ... an athletic trainer for the team throughout each season. Tonight, ... the Cleveland Gladiators at Amalie Arena; the game starts at ... us as it gives us the opportunity, to provide health ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... 2015 On February 21, 2015, ... the Stardust Penthouse on the rooftop of the ... leading sustainable product TV and film placement producer, ... event, which featured some of the world’s top ... and services. , “We were honored to have ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
Breaking Medicine News(10 mins):Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... ... new limited partner to its first venture fund, bolstering the fund’s ability to invest ... ... Bay Capital, LLC, has added a new limited partner to its first venture fund, ...
... ... to give the keynote speech at the Affiliate Summit 2010 event in NYC , ... (PRWEB) February 24, 2010 -- Twice ... and network about how to create and promote a successful online business. This year Jim ...
... , ... Unfortunately over the years, lawsuits and related investigations suggest some health plans have ... simply missing checkboxes on complex insurance forms. However, consumers seeking to appeal their ... appeal. , ...
... ... Services Providers. , ... Renton, WA (PRWEB) February 24, 2010 -- Parallels , worldwide leader in Cloud ... offerings for Apple environments with the introduction of the world’s first bare metal hypervisor ...
... ... small business. , ... (PRWEB) February 24, 2010 -- Verndale, a leading mid-market web technology and consultancy firm ... business, which is redefining the way websites are designed and managed. With Jumpstart, clients ...
... uninsured children, report says , WEDNESDAY, Feb. 24 (HealthDay ... of uninsured children with asthma by 75 percent by ... insurance programs and expanding eligibility, a new report suggests. ... care for kids with asthma costs an average of ...
Cached Medicine News:Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 2Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 3Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 4Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 2Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 2Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 4Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 2Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 3Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 4Health News:Verndale Announces the Release of Jumpstart 2Health News:Verndale Announces the Release of Jumpstart 3Health News:Existing Health Programs Could Help More Kids With Asthma 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: